Inocras Unveils ASCO 2026 Findings on Whole-Genome HRD Phenotyping to Predict PARP Inhibitor Response in Ovarian Cancer

Inocras Presents Real-World Evidence Supporting Whole-Genome HRD Profiling in Ovarian Cancer Treatment Inocras, a bioinformatics-driven precision oncology company specializing in whole-genome sequencing and advanced genomic analytics, has announced that new…

Read MoreInocras Unveils ASCO 2026 Findings on Whole-Genome HRD Phenotyping to Predict PARP Inhibitor Response in Ovarian Cancer

Agios Secures EU Approval for PYRUKYND® (Mitapivat) to Treat Adults with Thalassaemia, Announces Avanzanite Bioscience

Agios Secures EU Approval for PYRUKYND® (mitapivat) to Treat Adults Living with Thalassaemia, Announces Avanzanite Bioscience Avanzanite Bioscience B.V. has announced a major milestone in the treatment of rare blood…

Read MoreAgios Secures EU Approval for PYRUKYND® (Mitapivat) to Treat Adults with Thalassaemia, Announces Avanzanite Bioscience